The hypothyroidism paradox: treated thyroid status as a long-term catalyst for LDL-C target attainment post-percutaneous coronary intervention

Background Thyroid hormones (TH) exert critical permissive effects on insulin and catecholamines, indirectly modulating lipid metabolism. While hypothyroidism is linked to increased cardiovascular risk, the impact of treated thyroid status on achieving ESC-mandated LDL-C targets (<55 mg/dL) remains controversial. Methods We analyzed 368 consecutive post-Percutaneous Coronary Intervention (PCI) patients stratified by thyroid status: Treated Hypothyroidism (on levothyroxine) vs. Euthyroid Controls. LDL-C levels were collected at 0, 6, 12, and 24 months. The primary endpoint was LDL-C goal achievement (<55 mg/dL) at 6 months (2019 ESC/EAS Guidelines). Continuous variables (median [IQR]) were compared using the Mann-Whitney U test, and categorical outcomes using Fisher’s exact test. Adjusted multivariate logistic regression (age, sex, diabetes, hypertension, CKD) identified independent predictors of goal failure. Results Baseline LDL-C was comparable between groups (85.5 vs. 90.5 mg/dL; p=0.422).Temporal Dynamics: At 6 months, Treated Hypothyroid (H) patients showed a significant response lag compared to Controls (C) (62.5 vs. 56.5 mg/dL; p=0.008). However, this trend reversed long-term, with H patients achieving numerically lower LDL-C at 12 months (46.5 vs. 53.0 mg/dL; p=0.910) and 24 months (49.5 vs. 53.0 mg/dL; p=0.560).Multivariate Predictors: Despite the initial 6-month lag, treated hypothyroidism emerged as a potent independent protector against long-term goal failure (Adjusted OR: 0.106; 95% CI: 0.022–0.525; p=0.006). Conversely, Diabetes (OR: 3.13) and Male Sex (OR: 2.42) were confirmed as primary barriers.Clinical Safety: New coronary events showed no significant differences (21.7% H vs. 19.7% C; p=0.812). Safety profiles for NSTEMI, STEMI, and stent restenosis were comparable across all categories (all p > 0.05). Conclusions A "Hypothyroidism Paradox" exists in post-PCI management, characterized by a critical 6-month response lag where treated hypothyroid patients underperform compared to euthyroid controls (p=0.008), creating a vulnerable metabolic window where suboptimal thyroid replacement therapy (TRT) directly hinders early LDL-C clearance. Thyroid hormones might enhance biliary cholesterol elimination, increase hepatic LDL-receptor expression, and boost cholesterol ester transferase activity. Clinical practice must prioritize aggressive thyroid optimization within the first 6 months post-PCI to eliminate this early barrier to lipid targets. However, once biochemical euthyroidism is stabilized, TRT acts as a long-term metabolic catalyst, yielding superior goal attainment (aOR: 0.106; p=0.006) through the described mechanisms. The relative lag in euthyroid patients suggests that undiagnosed subclinical hypothyroidism could be a hidden factor in "statin resistance," warranting systematic TSH screening.